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Case Presentation and Review
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Abstract
Heparin Induced Thrombocytopenia (HIT) is an adverse effect of 
heparin therapy with possibly devastating consequences. We pres-
ent a case of HIT Type II. An in-depth review of HIT is presented, 
examining the important clinical symptoms and diagnostic indi-
cators. The treatment of HIT is then discussed, with an emphasis 
on current therapies. An extensive literature review has been per-
formed to present a comprehensive review of the causes, patho-
physiology and treatment of HIT.
Keywords: Heparin induced thrombocytopenia; Anticoagulation; 
PF4; HIT
Introduction
Heparin Induced Thrombocytopenia (HIT) is defined as a 
prothrombotic adverse effect of heparin therapy [1]. There 
are two types of HIT described. Type I is a non-immune, 
mediated, asymptomatic, transient drop in platelet count that 
occurs in some heparin treated patients. It is typically char-
acterized by a lesser fall in platelet count within the first two 
days after heparin initiation and often returns to normal with 
continued heparin administration [2]. The more serious form 
is Type II (HIT-II) is an immune-mediated disorder charac-
terized by the formation of antibodies against heparin-plate-
let factor 4 complexes. Since HIT Type I is of no clinical 
significance, this paper discusses HIT Type II. The frequency 
of HIT varies from 0.5% to 5%, depending on the patient 
population studied [3]. A meta-analysis noted an incidence 
of 2.6 percent [4].
Case History
A 70 years old woman was recently discharged following 
exploratory laparotomy for perforated duodenal ulcer with 
peritonitis. The patient presented on discharge day 4 with 
complaints of right-sided pleuritic chest pain that started the 
day after discharge. Pain was described as dull in nature, 5/10 
in severity, radiating to the right upper quadrant, aggravated 
by deep respiration and associated with cough productive 
of whitish sputum. The patient admitted to having chills but 
denies fever, shortness of breath or palpitations. The patient 
denied diarrhea or constipation. The patient denied having 
bloody or black stools. Her medical history included hypo-
thyroidism, hypertension, GERD and peptic ulcer disease.
Physical examination of the patient revealed an obese 
woman in mild distress. Her blood pressure was 122/77 
mmHg with a pulse of 86 beats per minute. She was breath-
ing 16 times/minute with an oxygen saturation of 100%. 
She was afebrile. On head and neck examination, her pupils 
were equal, round, reactive to light and accommodation. Her 
sclera was anicteric, revealing mild pallor. On cardiovascu-
lar exam, heart sounds were audible with regular rate and 
rhythm, normal S1 and S2, no murmurs. Her lung fields had 
decreased air entry bilaterally, right side greater than left. Her 
abdomen had surgical stables present along the midline with 
tenderness around the surgical site. Her extremities were 
symmetric without tenderness, cyanosis or pedal edema. Her 
pulses were present and palpable bilaterally.
Her blood chemistry panel revealed a serum sodium 
of 132 mmol/L, potassium of 3.6 mmol/L, chloride of 102 
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mmol/L, bicarbonate of 22 mmol/L, BUN of 15 mg/dL, cre-
atinine of 1.0 mg/dL and glucose of 92 mg/dL. Her Leuko-
cyte count was 16.0 x103 per µL, with 83% neutrophils. Her 
hemoglobin was 10.1 g/dL, hematocrit 29.5% and platelet 
count was 170 x103 per µL. Arterial blood gas sampling 
showed a pH of 7.48, PaCO2 of 33 mmHg, PaO2 of 77 
mmHg, and 97% and FiO2 of 21%. Chest x-ray revealed 
pneumonia in the right lung. The patient was diagnosed with 
hospital-acquired pneumonia and treated with intravenous 
fluids, IV Cefepime and Ciprofloxacin, Levothryoxine, Nex-
ium and Lotrel.
On hospital day 2, the patient reported improvement of 
symptoms. Vital signs were within normal limits. Leukocyte 
count was 8.0 x103 per uL. Hemoglobin was 8.6 g/dL, he-
matocrit was 26% and platelet count was 118 x103 per µL. 
CT scan revealed an improving pleural effusion. CBC was 
monitored with a discharge plan if leukocytes were trend-
ing downward. In the evening, the patient complained of left 
knee pain. Physical exam revealed erythema around the lat-
eral aspect of the left knee. Patient denied any trauma but 
states that the Flow-tron was a little tight. The Flow-tron was 
loosened and Tylenol was given for pain management. An 
hour later, the patient was re-evaluated. The entire left leg 
was noted to be swollen and now tender to touch. An as-
sessment of deep vein thrombosis (DVT) was made and the 
patient was started on heparin infusion.
On hospital day 5, lower extremity duplex scan showed 
acute thrombosis of left common femoral, superficial fem-
oral, popliteal, tibial and saphenous veins, with absence 
of flow and compressibility. The right popliteal vein also 
showed chronic re-canalized thrombosis. Leukocyte count 
was 9.9 x103 per µL, hemoglobin was 8.5 g/dL. Hemato-
crit 24.7%, platelet count was 89.2 x103 per µL. Platelets 
on admission were 170 x103 per µL. Serotonin release assay 
was 100%. The patient was diagnosed with HIT and started 
on Lepirudin. The leg swelling improved and platelet count 
improved to 197 x103 per µL.
Discussion
  
Clinical presentation
The initial sign of HIT usually is the development of throm-
Table 1. Pretest Probability of HIT
Pretest probability of HIT Score
Thrombocytopenia
Platelet count fall > 50% and nadir > 20,000 2 points
Platelet count fall 30 - 50 % or nadir 10 to 19,000 1 point
Platelet count fall < 30% or nadir < 10,000 0 points
Timing of platelet count fall
Clear onset between days 5 and 10 or platelet count fall at ≤ 1
day if prior heparin exposure within the last 30 days
2 points
Consistent with fall at 5 to 10 days but unclear (eg, missing
platelet counts), onset after day 10, or fall ≤ 1 day with prior
heparin exposure within 30 to 100 days
1 point
Platelet count fall at < 4 days without recent exposure 0 points
Thrombosis
Confirmed new thrombosis, skin necrosis, or acute systemic
reaction after IV unfractionated heparin bolus
2 points
Progressive or recurrent thrombosis, non-necrotizing
(erythematous) skin lesions, or suspected thrombosis which has
not been proven
1 point
None 0 points
Other causes
None apparent 2 points
Possible 1 point
Definite 0 points
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bocytopenia. The major manifestations of venous thrombosis 
are deep vein thrombosis (DVT) and pulmonary embolism 
(PE). Other manifestations include venous limb gangrene 
and cerebral sinus thrombosis [5]. Upper extremity DVT has 
also been described in HIT, but it is less common than lower 
extremity DVT [6]. Most upper extremity DVT occurred in 
patients with central venous catheters (CVC) and at the CVC 
site. Arterial thrombosis is less common in HIT but can lead 
to significant clinical complications including stroke, myo-
cardial infarction, acute limb ischemia from peripheral ar-
terial occlusion, or kidney infarction. White clot syndrome 
syndrome refers to platelet-rich aggregations leading to arte-
rial thrombosis [7]. Finally, skin necrosis on fat-rich areas 
such as the abdomen are commonly seen in HIT. Similar to 
warfarin-induced skin necrosis, erythema is followed by pur-
pura and hemorrhage leading to necrosis, however there are 
no deficiencies in anticoagulants [8].
Onset
There are three patterns for the onset of thrombocytopenia 
related to heparin exposure described [1, 9]. The most com-
mon pattern, typical-onset of HIT, occurs in 4 - 10 days after 
initial exposure to heparin with a fall in platelet count of > 
50 percent. The second pattern, delayed onset HIT, occurs 
a mean of 9 days after heparin stopped, but can be as long 
as 40 days [10-12]. Delayed HIT may account for 13 - 15% 
of all cases of HIT [13]. Early onset of HIT may be seen 
in about 30% of patients with persistent antibodies due to 
heparin therapy within the previous one to three months. The 
median time of platelet fall was 10.5 hours after the start of 
heparin administration [14].
Risk factors
The risk of developing HIT is related to many factors, in-
cluding the type of heparin product administered, route of 
administration, duration of therapy, patient population and 
previous exposure to heparin [15]. The use of unfractionated 
heparin (UFH) rather than low molecular weight heparin 
(LMWH), surgical rather than medical patients and female 
sex, have been associated with greater risk of developing 
HIT. Some surgical populations, such as cardiac transplant 
or neurosurgery patients have somewhat higher risk [16, 
17]. Antibodies are more likely to form in patients undergo-
ing cardiac surgery with an incidence as high as 15 to 20% 
than in orthopedic patients. Interestingly, orthopedic surgery 
patients compared with cardiac surgery patients, who are 
receiving unfractionated heparin post-operatively are less 
likely to develop heparin PF4-antibodies (14% versus 50% 
by antigen assay), yet more likely to develop HIT (4.9% ver-
sus 1.0%) [18, 19]. HIT was rarely found among patients less 
than 40 years of age as well as in women following delivery 
[20].
Pathophysiology
Following administration of heparin, a heparin neutralizing 
protein present within platelets (PF4) binds to heparin. This 
complex provokes the formation of antibodies, IgG and IgM, 
which bind to the heparin-PF4 complex. This leads to plate-
let activation. Platelet activation leads to release of more PF4 
with subsequent positive feedback. Also, platelet activation 
leads to platelet aggregation and premature removal which 
results in thrombocytopenia, release of micro-particles with 
pro-thrombic activity. Microvascular endothelial cells are 
activated, resulting in the release of interleukin-6, von Wil-
lebrand factor, and other adhesion molecules.
Diagnosis
Since time of onset can range between hours to several 
weeks, clinical suspicion for HIT is important in recognizing 
and starting therapy. The diagnosis of HIT is made on clini-
cal grounds since assays generally take a long time, whereas 
immediate therapy is critical to avoid often fatal complica-
tions of HIT. The following clinical scenarios should raise 
clinical suspicion in any patient received LMWH: onset of 
otherwise unexplained thrombocytopenia, venous or arte-
rial thrombosis associated with thrombocytopenia, a plate-
let count that has fallen 50 percent or more from a precious 
value, necrotic skin lesions at heparin injection sites or acute 
systemic reactions subsequent to IV heparin bolus adminis-
tration [21].
The criteria used in the diagnosis of HIT include [22]: 
(1) Normal platelet count before commencement of hepa-
rin. (2) Thrombocytopenia defined as a drop in platelet by 
30% or a drop of 50% from patient baseline. (3) Onset of 
thrombocytopenia typically 5 - 10 days after initiation of 
heparin treatment. (4) Acute thrombotic event. (5) Exclusion 
of thrombocytopenia after cessation of heparin. (6) HIT an-
tibody seroconversion.
Diagnosis can be made utilizing a clinical scoring sys-
tem based on the pretest probability of HIT known as the 
4Ts: Thrombocytopenia, Thrombosis, Timing, and other 
causes [23]. A score is determined based on the scoring sys-
tem summarized in Table 1. A score from 0 - 3 denotes low 
probability, 4 - 5 denotes an intermediate probability and 6 
- 8 denotes a high probability of HIT.
Diagnostic tests
Two general types of assays can be used to detect antibod-
ies [24, 25]. Most widely commercial enzyme immunoas-
says test for antibodies reactive against PF4/heparin or PF4/
polyvinyl sulfonate. ELISA test are very sensitive (91% to > 
97%), whereas a negative test strongly suggests the absence 
of HIT. In contrast, platelet activation assays detect HIT an-
tibodies upon their platelet-activating properties. The gold 
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standard for diagnostic tests for HIT is the 14 C-serotonin 
release assay. A positive test is the release of 14 C-seroton 
when therapeutic (0.1 U/ML) concentrations are used, rather 
than high (100 U/mL) concentrations. A positive test was 
stongly associated with thrombocytopenia starting 5 or more 
days after heparin exposure [26]. Heparin-induced platelet 
aggregation assay is a specific test for diagnosing HIT, but 
lacks sensitivity [25]. A positive test shows low background 
aggregation with no added heparin, aggregation with the ad-
dition of a low concentration of heparin, and absent aggrega-
tion with high heparin concentration.
Current therapies
When the diagnosis of HIT is confirmed, therapeutic doses 
of alternative non-heparin anticoagulants are usually re-
quired. Heparin treatments must be stopped immediately 
including heparin-bonded catheters and heparin flushes. Pa-
tients remain at risk for thrombosis from heparin cessation 
alone. Patients should be given a non-heparin anticoagulant. 
Coumadin should not be given. Prophylactic platelet trans-
fusions should not be given [11].
Direct thrombin inhibitors
Direct thrombin inhbitors which include Bivalirudin, Arg-
atroban and Lepiridin, directly inhibit procoagulant and pro-
thrombotic actions of thrombin. They do not require a cofac-
tor to inhibit thrombin. They are active against both free and 
clot-bound thrombin. They do not interact with or produce 
heparin dependent antibodies.
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